[{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Drug Prevents Heart Failure in Mouse Models","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MCB-613","moa":"Steroid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor Recruiting Melas Syndrome Patients for Phase 1 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Citrulline","moa":"Atherogenic","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Tessa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to \u2018Off-the-Shelf\u2019 CAR-T Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"CD30.CAR-EBVST Cells","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Immunai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed\/Refractory Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."}]

Find Clinical Drug Pipeline Developments & Deals by Baylor College of Medicine

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Baylor College of Medicine

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

INTERVIEW #SpeakPharma, VLOG #PharmaReel, DATA COMPILATION #PharmaFlow, 2 NEWS #PharmaBuzz

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed

02

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed

03

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed

04

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed

05

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed

06

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed

07

Baylor College of Medicine

U.S.A

Boulder Peptide 2024

Not Confirmed